Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that IDH1 p.R132C status confers therapeutic sensitivity to Azacitidine, Ivosidenib in patients with Acute Myeloid Leukemia.
This statement is based on a regulatory approval from the Health Canada:
TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.